Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Evaluation of Eluxadoline Effect on Cardiac Repolarization.Clinical pharmacology in drug development · 2018
   Trial
2. An Open-Label Study to Evaluate the Effect of Eluxadoline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Participants.Clinical pharmacology in drug development · 2022
   Article
3. Eluxadoline Loaded Solid Lipid Nanoparticles for Improved Colon Targeting in Rat Model of Ulcerative Colitis.Pharmaceuticals (Basel, Switzerland) · 2020
   Article
4. Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.Alimentary pharmacology & therapeutics · 2018
   Review
5. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.Drugs · 2017
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as